Movement disorders

Movement Disorders Parkinson’s Epilepsy

Parkinson’s ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

The Parkinson Balancing Act Normal Balance Parkinson’s Disease Drug Therapy in Parkinson’s Acetylcholine Dopamine

Metabolism of Levodopa Levodopa 3,O-Methyldopa Dopamine Degradation products COMT COMT inhibitors

Treatment of Parkinson’s Amantadine, benztropin, diphenhydramine, trihexyphenidyl Miscellaneous Carbidopa-levodopa/entacapone (Stalevo) Increase DA & inhibit metabolism Selegiline(Eldepryl), Tolcapone (Tasmar), Entacapone (Comtan) Inhibit DA Metabolism Levodopa-carbidopa (Sinemet) Bromocriptine, Pergolide(Permax) Pramipexole(Mirapex), Ropinirole(Requip) Increase DA Stimulate DA receptors Agents Drug Action

Drug Therapy ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Clinical Management ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

[object Object],[object Object],[object Object]

Points to Ponder ,[object Object],[object Object],[object Object],[object Object],[object Object]

Epilepsy ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Overview of Triggers ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Clinical Management of Epilepsy ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Seizure Type by Incidence Generalized Tonic-Clonic Partial Other

MOA of Anticonvulsants ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Pharmacologic Agents ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Management of Epilepsy ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Movement disorders

Recommandé

Recommandé

Contenu connexe

Tendances

Tendances (20)

Similaire à Movement disorders

Similaire à Movement disorders (20)

Plus de Diana Rangaves, PharmD, CEO

Plus de Diana Rangaves, PharmD, CEO (20)

Dernier

Dernier (20)

Movement disorders